Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin

Journal of Neuroscience Research

Volumn 88, Issue 11, 2010, Pages 2513-2523

  Li, Chao ^a,c   Biswas, S ^b   Li, Xingang ^c   Dutta, Aloke K ^b   Le, Weidong ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c SHANDONG UNIVERSITY   (China)

Author keywords

1 methyl 4 phenyl 1,2,3, 6 tetrahydropyridine; 5,6 dimethoxy 2 (di n propylamino)indan maleate; Animal models; BDNF; Brain derived neurotrophic factor; GDNF; Glial cell line derived factor; Lactacystin; MPTP; Neuroprotection; Parkinson's disease; U99194

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; BRAIN DERIVED NEUROTROPHIC FACTOR; D 264; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LACTACYSTIN; PROTEASOME INHIBITOR; TOXIN; UNCLASSIFIED DRUG; (5,6-DIMETHOXYINDAN-2-YL)DIPROPYLAMINE; ACETYLCYSTEINE; BIPHENYL DERIVATIVE; CYSTEINE PROTEINASE INHIBITOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; INDAN DERIVATIVE; N6-(2-(4-(BIPHENYL-4-YL)PIPERAZIN-1-YL)ETHYL)-N6-PROPYL-4,5,6,7-TETRAHYDROBENZO(D)THIAZOLE-2,6-DIAMINE; NEUROPROTECTIVE AGENT; PIPERAZINE DERIVATIVE; PROTEASOME; THIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL LOSS; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SCREENING; ENZYME INHIBITION; GLIA CELL; MALE; MEDIAL FOREBRAIN BUNDLE; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BODY EQUILIBRIUM; BRAIN; BRAIN LEVEL; C57BL MOUSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; METABOLISM; MOTOR ACTIVITY; MPTP POISONING; NEOSTRIATUM; PARKINSON DISEASE, SECONDARY; PATHOLOGY; PHYSIOLOGY; TOXICITY;

ACETYLCYSTEINE; ANIMALS; BIPHENYL COMPOUNDS; BRAIN; BRAIN CHEMISTRY; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYSTEINE PROTEINASE INHIBITORS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; IMMUNOHISTOCHEMISTRY; INDANS; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; PIPERAZINES; POSTURAL BALANCE; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, DOPAMINE D3; THIAZOLES;

EID: 77955346226     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22405     Document Type: Article

References (37)

1. Baquet ZC, Bickford PC, Jones KR. 2005. Brainderived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 25:6251-6259.
2. Bardgett ME, Depenbrock M, Downs N, Points M, Green L. 2009. Dopamine modulates effort-based decision making in rats. Behav Neurosci 123:242-251.
3. Biswas S, Hazeldine S, Ghosh B, Parrington I, Kuzhikandathil E, Reith ME, Dutta AK. 2008a. Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl- piperazin-1-yl) ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity. J Med Chem 51:3005-3019.
4. Biswas S, Zhang S, Fernandez F, Ghosh B, Zhen J, Kuzhikandathil E. 2008b. Further structure-activity relationships study of hybrid 7-{[2-(4- phenylpiperazin-1-yl)ethyl] propylamino}-5,6,7,8-tetrahydronaphtha len-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action. J Med Chem 51:101-117.
5. Block ML, Zecca L, Hong JS. 2007. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57-69. (Pubitemid 46011999)
6. Chen S, Zhang X, Yang D, Du Y, Li L, Li X, Ming M, Le W. 2008. D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett 582:603-610.
7. Dauer W, Przedborski S. 2003. Parkinson's disease: mechanisms and models. Neuron 39:889-909.
8. Deierborg T, Soulet D, Roybon L, Hall V, Brundin P. 2008. Emerging restorative treatments for Parkinson's disease. Prog Neurobiol 85:407-432.
9. Du F, Li R, Huang Y, Li X, Le W. 2005. Dopamine D3 receptor-preferring agonists induce Neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22:2422-2430.
10. Glaser JR, Glaser EM. 2000. Stereology, morphometry, and mapping: the whole is greater than the sum of its parts. J Chem Neuroanat 20:115-126.
11. + toxicity: role of BDNF gene expression. Brain Res Mol Brain Res 41:14-26.
12. Jackson LV, Przedborski S. 2007. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2:141-151.
13. Jankovic J. 2008. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatr 79:368-376.
14. Jenner P. 2007. Oxidative stress in Parkinson's disease. Hdbk Clin Neurol 83:507-520.
15. Johnstone M, Gearing AJ, Miller KM. 1999. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol 93:182-193.
16. Joyce JN, Millan MJ. 2007. Dopamine D3 receptor agonists for protection and repair in Parkinson's disease. Curr Opin Pharmacol 7:100-105. (Pubitemid 46238043)
17. Kling-Petersen T, Ljung E, Svensson K. 1995. Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm 102:209-220.
18. Lida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. 1999. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 838:51-59.
19. McNaught KS, Olanow CW. 2006. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. Neurobiol Aging 27:530-545. (Pubitemid 43290522)
20. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: from structure to function. Physiol Rev 78:189-225.
21. Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y. 1985. A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50:435-441.
22. Paxinos G, Franklin KB. 2001. The mouse brain in stereotaxic coordinates, 2nd ed. San Diego: Academic Press.
23. Petrucelli L, Dawson TM. 2004. Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 36:315-20. (Pubitemid 38789286)
24. Porritt MJ, Batchelor PE, Howells DW. 2005. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol 192:226-234.
25. Presgraves SP, Borwege S, Millan MJ, Joyce JN. 2004. Involvement of dopamine D2/D3 receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp Neurol 190:157-170.
26. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G. 2000. The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135-142.
27. Ramirez AD, Wong SK, Menniti FS. 2003. Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. Eur J Pharmacol 475:29-35.
28. Rousselet E, Joubert C, Callebert J, Parain K, Tremblay L, Orieux G, Launay JM, Cohen-Salmon C, Hirsch EC. 2003. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis 14:218-228. (Pubitemid 37311286)
29. Shannon KM, Bennett JP Jr, Friedman JH. 1997. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 49:724-728.
30. Sokoloff P, Giros B, Martres MP, Andrieux M, Besancon R, Pilon C, Bouthenet ML, Souil E, Schwartz JC. 1992. Localization and function of the D3 dopamine receptor. Arzneimittelforschung 42:224-230.
31. Van Kampen JM, Eckman CB. 2006. Dopamine D3 receptor agonist delivery to a model of Parkinson's disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 26:7272-7280.
32. West MJ, Slomianka L, Gundersen HJ. 1991. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497.
33. Winner B, Desplats P, Hagl C, Klucken J, Aigner R, Ploetz S, Laemke J, Karl A, Aigner L, Masliah E, Buerger E, Winkler J. 2009. Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model. Exp Neurol 219:543-552.
34. Wooten GF. 1997. Neurochemisty and neuropharmacology of Parkinson's disease. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. New York: McGraw-Hill. p 153-160.
35. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim BH, Le W. 2007. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21:3835-3844.
36. Zou L, Xu J, Jankovic J, He Y, Appel SH, Le W. 2000. Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice. Neurosci Lett 281:167-170.
37. Zuccato C, Cattaneo E. 2009. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 5:311-322.